{"entity":{"id":"nct06578624","kind":"trial","name":"Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SA53-OS (phase 1) in advanced solid tumours, run by Lamassu Bio Inc, now recruiting.","summary":"Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06578624 by Lamassu Bio Inc, with 70 participants planned, started 2025-03-10 and due to reach its primary completion in 2026-12. Interventions recorded: SA53-OS (phase 1) and SA53-OS (phase 2).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06578624","url":"https://clinicaltrials.gov/study/NCT06578624"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06578624","phase":"1/2","setting":"A Phase 1/2a, Open-Label Study of Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SA53-OS, an MDM2 Inhibitor, in Patients With Locally Advanced or Metastatic p53 Wild-Type Solid Tumors","sponsor":"Lamassu Bio Inc","enrolled":70,"outcomes":[]},"route":"/trials/nct06578624/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}